Agile Therapeutics (NASDAQ:AGRX) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Agile Therapeutics (NASDAQ:AGRX) in a research report sent to investors on Sunday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, Maxim Group reaffirmed a hold rating on shares of Agile Therapeutics in a research note on Monday, March 18th.

Agile Therapeutics Stock Performance

Shares of AGRX opened at $0.40 on Friday. The business’s 50 day moving average is $0.56 and its 200 day moving average is $1.38. The company has a market capitalization of $2.74 million, a PE ratio of -0.04 and a beta of 1.42. Agile Therapeutics has a 12-month low of $0.20 and a 12-month high of $6.97.

Agile Therapeutics (NASDAQ:AGRX) last released its quarterly earnings data on Thursday, March 28th. The specialty pharmaceutical company reported ($1.46) earnings per share (EPS) for the quarter. The business had revenue of $3.62 million during the quarter.

Hedge Funds Weigh In On Agile Therapeutics

A hedge fund recently raised its stake in Agile Therapeutics stock. Armistice Capital LLC increased its stake in shares of Agile Therapeutics, Inc. (NASDAQ:AGRX) by 10.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 108,000 shares of the specialty pharmaceutical company’s stock after purchasing an additional 10,000 shares during the quarter. Armistice Capital LLC owned 3.65% of Agile Therapeutics worth $211,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 10.92% of the company’s stock.

About Agile Therapeutics

Agile Therapeutics, Inc, a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.